Systems biology based drug repositioning for development of cancer therapy.


Journal

Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218

Informations de publication

Date de publication:
01 2021
Historique:
received: 22 07 2019
revised: 23 09 2019
accepted: 24 09 2019
pubmed: 1 10 2019
medline: 1 3 2022
entrez: 1 10 2019
Statut: ppublish

Résumé

Drug repositioning is a powerful method that can assists the conventional drug discovery process by using existing drugs for treatment of a disease rather than its original indication. The first examples of repurposed drugs were discovered serendipitously, however data accumulated by high-throughput screenings and advancements in computational biology methods have paved the way for rational drug repositioning methods. As chemotherapeutic agents have notorious side effects that significantly reduce quality of life, drug repositioning promises repurposed noncancer drugs with little or tolerable adverse effects for cancer patients. Here, we review current drug-related data types and databases including some examples of web-based drug repositioning tools. Next, we describe systems biology approaches to be used in drug repositioning for effective cancer therapy. Finally, we highlight examples of mostly repurposed drugs for cancer treatment and provide an overview of future expectations in the field for development of effective treatment strategies.

Identifiants

pubmed: 31568815
pii: S1044-579X(19)30265-2
doi: 10.1016/j.semcancer.2019.09.020
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-58

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Beste Turanli (B)

Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden; Department of Bioengineering, Marmara University, Istanbul, Turkey; Department of Bioengineering, Istanbul Medeniyet University, Istanbul, Turkey.

Ozlem Altay (O)

Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden.

Jan Borén (J)

Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital Gothenburg, Sweden.

Hasan Turkez (H)

Department of Molecular Biology and Genetics, Erzurum Technical University, Erzurum 25240, Turkey.

Jens Nielsen (J)

Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.

Mathias Uhlen (M)

Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden.

Kazim Yalcin Arga (KY)

Department of Bioengineering, Marmara University, Istanbul, Turkey.

Adil Mardinoglu (A)

Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden; Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London SE1 9RT, United Kingdom. Electronic address: adilm@scilifelab.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH